Patents by Inventor Silvio Traversa
Silvio Traversa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230137491Abstract: The present invention relates to CD271-interacting peptides and derivatives thereof and to their use as a medicament for the treatment of CD271-related diseases, in particular for the treatment of melanoma and other CD271-related skin diseases.Type: ApplicationFiled: April 9, 2021Publication date: May 4, 2023Applicant: SINTICA BIOTECH SOCIETÀ A RESPONSABILITÀ LIMITATA SEMPLIFICATAInventors: Roberta LOTTI, Elisabetta PALAZZO, Marika QUADRI, Alessandra MARCONI, Carlo PINCELLI, Silvio TRAVERSA
-
Publication number: 20190209472Abstract: Topical formulations to treat skin conditions, such as psoriasis, are provided in which a polymer conjugate of an indolocarbazole exhibits reduced systemic exposure. An example formulation includes the TrkA antagonist, SNA-120, together with a preservative/antioxidant, a preservative/solvent, a solvent, a solvent/moisturizing agent, a stiffening agent, and one or more emollients/emulsifying agents.Type: ApplicationFiled: December 3, 2018Publication date: July 11, 2019Inventors: Valentina Mainero, Silvio Traversa
-
Publication number: 20170304398Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: April 28, 2017Publication date: October 26, 2017Applicant: Creabilis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 9707298Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: GrantFiled: December 27, 2012Date of Patent: July 18, 2017Assignee: CREABILIS THERAPEUTICS S.R.L.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Patent number: 8926955Abstract: The present invention relates to a process for the preparation of polymer conjugates of indolocarbaxole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterized by a 5-member oxazolidindionic cyclic structure. These novel polymer conjugates are obtained through the novel synthetic route with high purity and high yields.Type: GrantFiled: December 22, 2009Date of Patent: January 6, 2015Assignee: Creabilis S.A.Inventors: Raffaella Bagnod, Luca Beccaria, Luisa Bertarione Rava Rossa, Domenico Criscuolo, Chiara Lorenzetto, Valentina Mainero, Alessandra Marconi, Carlo Pincelli, Silvio Traversa
-
Patent number: 8673347Abstract: The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. The invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of a) neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system; b) dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis; and c) NGF-related pain.Type: GrantFiled: August 25, 2006Date of Patent: March 18, 2014Assignee: Creabilis Therapeutics S.p.A.Inventors: Silvio Traversa, Raffaella Bagnod, Domenico Barone, Luisa Bertarione Rava Rossa, Silvano Fumero, Valentina Mainero, Alessandra Marconi, Cecilia Oderda, Carlo Pincelli, Chiara Lorenzetto, Luca Beccaria
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 8546547Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: GrantFiled: September 14, 2007Date of Patent: October 1, 2013Assignee: Creabilis Therapeutics S.p.A.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Publication number: 20110311451Abstract: The present invention relates to a process for the preparation of polymer conjugates of i?dolocarbazole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterised by a 5-member oxazolidindionic cyclic structure.Type: ApplicationFiled: December 22, 2009Publication date: December 22, 2011Applicant: CREABILIS S.A.Inventors: Raffaella Bagnod, Luca Beccaria, Luisa Bertarione Rava Rossa, Domenico Criscuolo, Chiara Lorenzetto, Valentina Mainero, Alessandra Marconi, Carlo Pincelli, Silvio Traversa
-
Publication number: 20090324677Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: September 14, 2007Publication date: December 31, 2009Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Publication number: 20090191253Abstract: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis.Type: ApplicationFiled: January 29, 2007Publication date: July 30, 2009Applicants: Creabilis Therapeutics S.P.A., Bio3Research srlInventors: Silvano FUMERO, Francesco PILATO, Domenico BARONE, Luisa BERTARIONE RAVA ROSSA, Valentina MAINERO, Silvio TRAVERSA
-
Publication number: 20080193517Abstract: The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system.Type: ApplicationFiled: August 25, 2006Publication date: August 14, 2008Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvio Traversa, Raffaella Bagnod, Domenico Barone, Luisa Bertarione Rava Rossa, Silvano Fumero, Valentina Mainero, Alessandra Marconi, Cecilia Oderda, Carlo Pincelli, Chiara Lorenzetto, Luca Beccaria
-
Publication number: 20070293422Abstract: Peptides and derivatives or analogs thereof are provided for having ?-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.Type: ApplicationFiled: April 29, 2004Publication date: December 20, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Luca Barbero, Pierandrea Esposito, Silvio Traversa
-
Patent number: 7256258Abstract: A method is described for a method for the regioselective liquid-phase pegylation of GRF, which increases the yield of the GRF-PEG conjugate having 1 PEG molecule covalently bound to the e-amino group of Lys12. This method is characterized in that the reaction is carried out in a structuring solvent, such as trifluorethanol.Type: GrantFiled: October 3, 2001Date of Patent: August 14, 2007Assignee: Ares Trading S.A.Inventors: Gilles Piquet, Luca Barbero, Silvio Traversa, Monica Gatti
-
Publication number: 20040176569Abstract: A method is described for a method for the regioselective liquid-phase pegylation of GRF, which increases the yield of the GRF-PEG conjugate having 1 PEG molecule covalently bound to the e-amino group of Lys12. This method is characterized in that the reaction is carried out in a structuring solvent, such as trifluorethanol.Type: ApplicationFiled: September 3, 2003Publication date: September 9, 2004Inventors: Gilles Piquet, Luca Barbero, Silvio Traversa, Monica Gatti